NCT03474978

Brief Summary

This study examines whether there is an association between the PICC insertion site and the complications necessitating PICC removal in neonates admitted to neonatal intensive care unit.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
320

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 14, 2018

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 23, 2018

Completed
7 months until next milestone

Study Start

First participant enrolled

October 19, 2018

Completed
7.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

May 19, 2023

Status Verified

May 1, 2023

Enrollment Period

7.2 years

First QC Date

March 14, 2018

Last Update Submit

May 17, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Primary outcome is the presence of any complication which necessitates PICC removal

    Line infiltration will be defined as extravasation of fluid into soft tissue around the region of the catheter tip. Line occlusion will be defined as inability to infuse fluid, resulting in removal of line. Phlebitis will be defined as presence of a linear red streak developing along the superficial veins from the catheter insertion site. Line associated thrombosis will be defined as ultrasound proven evidence of an occlusive thrombus in an anatomic location in proximity to the site of PICC.CLABSI will be defined according to Center for Disease Control definitions 26, that is, (1) confirmed primary bloodstream infection with (2) one of following clinical signs of infection (fever, hypothermia, apnea, or bradycardia) and (3) presence of central catheter at the time of or within 48 hours before the onset of the infection. Major life-threatening complications will include pleural effusion, pericardial effusion and cardiac tamponade, retroperitoneal extravasation.

    Through study completion, within 4 weeks

Secondary Outcomes (1)

  • Secondary outcome will be time to complication post insertion

    Through study completion, within 4 weeks

Study Arms (2)

Upper Extremity Insertion

EXPERIMENTAL

Peripherally Inserted Central Venous Cather (PICC) inserted in upper extremity

Device: Peripherally Inserted Central Venous Cather (PICC)

Lower Extremity Insertion

EXPERIMENTAL

Peripherally Inserted Central Venous Cather (PICC) inserted in lower extremity

Device: Peripherally Inserted Central Venous Cather (PICC)

Interventions

Location of the PICC insertion will be randomized and compared

Lower Extremity InsertionUpper Extremity Insertion

Eligibility Criteria

AgeUp to 4 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Neonates of all gestational ages admitted to Foothills Medical Centre and Alberta Children's Hospital Neonatal Intensive Care Unit (NICU)
  • Peripherally inserted central venous catheter (PICC) line insertion planned as part of NICU care
  • Venous access available in both upper(above umbilicus) and lower body

You may not qualify if:

  • Local infection at potential site of insertion
  • Hemangioma, lymphangioma or malformations in the region of insertion
  • Major chromosomal anomalies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Foothills Medical Centre

Calgary, Alberta, T2N2T9, Canada

RECRUITING

Study Officials

  • Amuchou Soraisham, MD

    University of Calgary

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Amuchou Soraisham, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Neonatologist

Study Record Dates

First Submitted

March 14, 2018

First Posted

March 23, 2018

Study Start

October 19, 2018

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

May 19, 2023

Record last verified: 2023-05

Locations